PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.
The user experienced scalp irritation from a Finasteride and Minoxidil spray and serum. They are considering switching to foam, oral treatments, or another provider.
A group buy for hair loss treatments including Harmine 19a, TM5614, Abiraterone Acetate, and others. A compound, BMS-202, that can potentially reverse gray hair is also mentioned.
A 42-year-old user shares progress on hair loss treatment using finasteride, topical minoxidil, and dermarolling. They seek advice on obtaining Minoxidil pills in Europe.
A user's two month update on their hair loss journey and the treatments they are trying, which include exosome injections, minoxidil, finasteride, and RU58841.
Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.
Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.
The conversation discusses using USB microscopes for scalp photos and provides a link to an overview of trichoscopy. Treatments mentioned include Minoxidil, finasteride, and RU58841.
PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.
The conversation discusses a hair loss treatment regimen involving minoxidil, finasteride, RU58841, JXL069, and nizoral shampoo. The user reports seeing new black dots in areas where hair hasn't grown in years, suggesting potential regrowth.
The user shared progress pictures after using oral finasteride 1mg daily and topical minoxidil 5% twice a day for 107 days, noting initial shedding that stabilized. Other users discussed application techniques, dosage, and shared encouragement and questions about side effects and results.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Pyrilutamide Phase 2 results are expected in June 2022, with hopes for a better alternative to current treatments.
User experienced positive results with CosmeRNA for hair loss after 1.5 weeks, including reduced scalp itchiness, less oiliness, and decreased shedding. They have not felt any side effects and are happy with the treatment so far.
The user has been using 0.5 mg oral finasteride and recently switched to 2.5 mg oral minoxidil from topical application. They are observing potential early regrowth with longer baby hairs.
The user experienced new hair growth after switching from oral finasteride to topical RU58841 with minoxidil and undergoing stem cell therapy. They noticed new hairs at the hairline and temples, but are unsure which treatment is responsible.
The conversation is about the delay in receiving updates on the HMI-115 phase 1 trial for hair loss. No specific treatments are mentioned in the conversation.
2 Deoxy D Ribose may promote hair growth and aid wound healing, potentially enhancing microneedling effects. Users discuss its combination with microneedling for better hair growth results.
A transgender individual began MTF HRT with estradiol and spironolactone at 39 and is monitoring hair regrowth before starting minoxidil. They are hopeful about not needing wigs permanently.
The potential accuracy and trustworthiness of websites selling Pyrilutamide, a drug related to hair loss treatments such as Minoxidil, Finasteride, and RU58841; and whether Pyrilutamide is four times stronger than RU58841.
The user is using minoxidil and finasteride to treat hair loss and is concerned about shedding and potential aggressive hair loss. They noticed some regrowth in trichoscopy pictures but are unsure about real-life changes.
GT20029 and CosmeRNA are both potential hair loss treatments; GT20029 breaks down the androgen receptor, while CosmeRNA prevents its production. Continuous use is needed, but less frequently than current treatments like Minoxidil and Finasteride.
User shared progress on hair regrowth using Fin 1 mg/day for 4 years, Min 2x/day for 3 years, Estradiol 4mg/day, and Spironolactone 100mg/day for 3.5 months. They noted significant hairline recovery and advised against HRT for cis men due to feminizing effects.
This conversation was about a user's experience with hair loss treatments over two years, using finasteride and minoxidil which resulted in significant improvement.
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.
A European individual planning to go to China is seeking information on how to participate in HMI-115 trials for Androgenetic Alopecia. They've tried contacting Mrs. Yang and Mr. Wang for assistance but haven't received a response.
The user is experiencing reduced hair shedding and increased hair density after using finasteride, minoxidil, derma rolling, granactive retinoid, and Nizoral, while also taking testosterone and aromatase inhibitors. They question if they are a hyper responder to the treatments, despite mixed feedback from others about visible progress.
Diffuse thinners find shopping challenging due to harsh overhead lighting, but H&M's side lighting in fitting rooms is more flattering. Many users humorously suggest banning overhead lighting to improve the shopping experience.